Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

News Conference News ESC Heart Failure 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

May 19, 2025

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

April 15, 2024

Coincidental Nonischemic Cardiomyopathy Impacts Prognosis in CAD

News Conference News AHA 2023

Coincidental Nonischemic Cardiomyopathy Impacts Prognosis in CAD

November 09, 2023

Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions

News Conference News ACC 2023

Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions

Michael O'Riordan

March 07, 2023

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

October 07, 2022

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

News Conference News STS 2022

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Michael O'Riordan

February 04, 2022

Modified Surgical MV Repair Stands Up to Replacement

News Conference News STS 2022

Modified Surgical MV Repair Stands Up to Replacement

Michael O'Riordan

February 03, 2022

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

News Conference News

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

November 16, 2021

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

ULTIMATE: IVUS Superior to Angiography at Guiding PCI, With Less TVF by 1 Year

News Conference News TCT 2018

ULTIMATE: IVUS Superior to Angiography at Guiding PCI, With Less TVF by 1 Year

September 24, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.